What happened, in summary

A 51-year-old woman sought care for persistent cough and sputum production and was diagnosed with small-cell lung cancer in the left lower lobe. Imaging showed a large lung mass with enlarged hilar and mediastinal lymph nodes but no distant spread, corresponding to Stage III disease. She strongly preferred a treatment approach that could include surgery. She received 5 cycles of neoadjuvant etoposide and cisplatin combined with serplulimab. The lung mass shrank substantially after treatment, with an ongoing partial response on imaging. Forty-seven days after completing neoadjuvant therapy, she underwent left lower lobectomy with lymph-node dissection. Pathology found no remaining viable cancer, confirming a pathological complete response. After surgery, she received 1 additional cycle of etoposide, cisplatin, and serplulimab and did not continue maintenance serplulimab. Follow-up imaging was performed every 2 months. Through 12 months from the start of neoadjuvant therapy, no recurrence or metastasis was detected. No treatment-related adverse effects were reported during the treatment course.